Hydralazine (hydrochloride)

Hydralazine is an orally bioavailable vasodilator and antihypertensive agent.¹ It decreases DNA methylation in Jurkat cells at a concentration of 10 μM and inhibits extracellular and intracellular production of reactive oxygen species (ROS) in rat macrophages activated by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) at a concentration of 100 μM.^2,3 Hydralazine (100 μM) also decreases nitric oxide production and mRNA expression of inducible nitric oxide synthase (iNOS) in rat macrophages activated by LPS (Item Nos. 19660| 19661) and interferon-γ (IFN-γ).³ It reduces contraction of rat aortic arterial strips induced by potassium and norepinephrine (Item No. 16673; IC₅₀s = 2.2 and 3.06 mM, respectively).⁴ Hydralazine (2.6 mg/kg) lowers mean arterial blood pressure (MAP) by 41.76% in conscious rats.⁵ Formulations containing hydralazine have been used in the treatment of high blood pressure and heart failure.

WARNING This product is not for human or veterinary use.

1. Cohn, J.N., McInnes, G.T., and Shepherd, A.M. Direct-acting vasodilators. J. Clin. Hypertens. (Greenwich) 13(9), 690-692 (2011).

2. Cornacchia, E., Golbus, J., Maybaum, J., et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140(7), 2197-2200 (1988).

3. Leiro, J.M., Alvarez, E., Arranz, J.A., et al. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int. Immunopharmacol. 4(2), 163-177 (2004).

4. Orallo, F., Gil-Longo, J., Bardán, B., et al. Comparison of the effects of hydralazine and nifedipine on contractions and 45Ca influx of rat aorta. J. Pharm. Pharmacol. 43(5), 356-359 (1991).

5. Siddiqui, A.A., Mishra, R., Shaharyar, M., et al. Triazole incorporated pyridazinones as a new class of antihypertensive agents: Design, synthesis and in vivo screening. Bioorg. Med. Chem. Lett. 21(3), 1023-1026 (2011).